RxDoctor Payments Data

Roger Willette, MD

Internal Medicine · Houston, TXNPI 1831138445

Payments from drug & device makers

$1,191in general payments, 2019–2025

Across 67 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$167
  • Johnson & Johnson$133
  • Pfizer$88
  • Novartis$85
  • Astellas Pharma US Inc$78
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$58
  • plus $582 from 18 others

What the payments were for

  • Food & beverage$1,191100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,191 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$205,360
Medicare patients
367
Services billed
2,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate62$84,521
OzempicSemaglutide59$70,921
FarxigaDapagliflozin Propanediol60$69,148
EliquisApixaban39$51,692
JardianceEmpagliflozin21$18,385
MounjaroTirzepatide11$17,981
MyrbetriqMirabegron13$16,922
Janumet XrSitagliptin Phos/Metformin Hcl14$16,637
XareltoRivaroxaban15$14,492
RybelsusSemaglutide11$14,449
Breo ElliptaFluticasone/Vilanterol14$8,012
Rosuvastatin Calcium399$5,913
SymbicortBudesonide/Formoterol Fumarate18$5,673
Levothyroxine Sodium277$3,744
Atorvastatin Calcium328$3,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$42$85,37070 claims
AstraZenecaFarxiga, Symbicort$167$74,82178 claims
PfizerEliquis$88$51,69239 claims
Lilly USA, LLCMounjaro$41$17,98111 claims
Astellas Pharma US IncMyrbetriq$78$16,92213 claims
Johnson & JohnsonXarelto$133$14,49215 claims
GSKBreo Ellipta$53$8,01214 claims
Sanofi-aventis U.S. LLCLantus$26$2,26512 claims
AbbVieSynthroid$57$1,98537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →